US equities |
META $620.19 ▼-1.64% MU $928.76 ▲+2.77% NVDA $217.94 ▲+0.90% TSLA $407.46 ▲+4.04% SPCX $148.58 ▲+1.14% AAPL $347.10 ▲+0.93% AMD $560.26 ▲+5.45% MSFT $531.33 ▼-0.24%
FinancialContent

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

3.220 +0.300 (+10.27%)
Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
33 34 Next >
Lexaria Bioscience Corp. (NASDAQ: LEXX) Banking on DehydraTECH(TM) Technology for Major 2024 Growth
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Banking on DehydraTECH(TM) Technology for Major 2024 Growth
Via CannabisNewsWire
Topics Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO for Second DehydraTECH-Powered GLP-1 Human Pilot Study
Via Investor Brand Network
Topics Intellectual Property
News headline image
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
Via ACCESSWIRE
News headline image
Why Lexaria Bioscience (LEXX) Shares Are Moving ↗
Lexaria Bioscience shares are trading lower by 6.5% Thursday morning. The company finalized agreements for a registered direct offering. 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study
Via Investor Brand Network
Topics Intellectual Property
News headline image
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study
Via CannabisNewsWire
Topics Intellectual Property
News headline image
7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial
Via Investor Brand Network
Topics Intellectual Property
News headline image
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6 Million Registered Direct Offering
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6 Million Registered Direct Offering
Via CannabisNewsWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering
Via CannabisNewsWire
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Doubles Down on GLP-1 Clinical Studies for 2024; Terms 2023 as its Most Successful and Active Year of R&D
Via Investor Brand Network
News headline image
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on $3.6M Registered Direct Offering
Via Investor Brand Network
Topics Intellectual Property
News headline image
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks off 2024 with FDA IND Submission for its HYPER-H23-1 Phase 1b Human Clinical Trial
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Improves Delivery of GLP-1 Drug to Bloodstream
Via Investor Brand Network
Topics Intellectual Property
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) CEO, Chris Bunka, Shares 2023 Company Update and 2024 Roadmap in Annual Letter
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2024 GLP-1 Human and Animal Studies Roadmap
Via Investor Brand Network
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Submission of IND for Planned Phase 1b Hypertension Trial
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
33 34 Next >